New cell therapy tested for Tough-to-Treat blood cancer

NCT ID NCT07399444

Summary

This early-stage study is testing a new cell therapy called LVIVO-TaVec400 for people with multiple myeloma that has returned or stopped responding to standard treatments. The study will enroll about 38 adults who have already tried at least three other therapies. Researchers will first find the safest dose and then check if the treatment helps control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Beijing GoBroad Boren Hospital

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.